Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

181. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. (Full text)

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. We evaluated the efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer who were at high risk for the development of metastasis.We conducted a double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic castration-resistant prostate cancer (...) of the trial regimen was 10.6% in the apalutamide group and 7.0% in the placebo group. The following adverse events occurred at a higher rate with apalutamide than with placebo: rash (23.8% vs. 5.5%), hypothyroidism (8.1% vs. 2.0%), and fracture (11.7% vs. 6.5%).Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo. (Funded by Janssen Research and Development; SPARTAN

2018 NEJM PubMed

182. Localised prostate cancer - immediate treatment, or not?

Localised prostate cancer - immediate treatment, or not? Prescrire IN ENGLISH - Spotlight ''Localised prostate cancer - immediate treatment, or not?'', 1 February 2018 {1} {1} {1} | | > > > Localised prostate cancer - immediate treatment, or not? Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight In the February issue of Prescrire International (...) : Localised prostate cancer - immediate treatment, or not? FREE DOWNLOAD In patients with localised prostate cancer, the principal therapeutic options are: monitoring without initial treatment, prostatectomy and radiotherapy. Results of a comparative randomised trial have provided some useful data for providing information to patients. Full text available for free download. Summary In a randomised trial including 1643 patients with localised prostate cancer, all detected by PSA screening, the mortality

2018 Prescrire

183. Ablative techniques for the treatment of localised prostate cancer

Ablative techniques for the treatment of localised prostate cancer Health Policy Advisory Committee on Technology Technology Brief Update Ablative techniques for the treatment of localised prostate cancer December 2016 © State of Queensland (Queensland Department of Health) 2016 This work is licensed under a Creative Commons Attribution Non-Commercial No Derivatives 3.0 Australia licence. In essence, you are free to copy and communicate the work in its current form for non-commercial purposes (...) from the Australian Safety and Efficacy Register of New Interventional Procedures – Surgical (ASERNIP-S). Ablative techniques for localised prostate cancer: December 2016 i 2016 Summary of findings Currently, the most common treatments for localised Prostate cancer (PCa) are radical prostatectomy, active surveillance, external beam radiation therapy and brachytherapy. Focal therapy could potentially prevent complications associated with whole-gland therapy (urinary incontinence/retention, erectile

2018 COAG Health Council - Horizon Scanning Technology Briefs

184. Comparative effectiveness review of cryoablation for salvage treatment of recurrent prostate cancer following radiotherapy

Comparative effectiveness review of cryoablation for salvage treatment of recurrent prostate cancer following radiotherapy Comparative effectiveness review of cryoablation for salvage treatment of recurrent prostate cancer following radiotherapy Comparative effectiveness review of cryoablation for salvage treatment of recurrent prostate cancer following radiotherapy HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Comparative effectiveness review of cryoablation for salvage treatment of recurrent prostate cancer following radiotherapy. Lansdale: HAYES, Inc. Directory Publication. 2017 Authors' conclusions Cryoablation of the prostate gland provides a minimally invasive treatment option for the management of localized prostate cancer. The technique uses percutaneously inserted cryoprobes to freeze and thereby

2018 Health Technology Assessment (HTA) Database.

185. Comparative effectiveness review of cryoablation for primary treatment of localized prostate cancer

Comparative effectiveness review of cryoablation for primary treatment of localized prostate cancer Comparative effectiveness review of cryoablation for primary treatment of localized prostate cancer Comparative effectiveness review of cryoablation for primary treatment of localized prostate cancer HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation HAYES, Inc. Comparative effectiveness review of cryoablation for primary treatment of localized prostate cancer. Lansdale: HAYES, Inc. Directory Publication. 2017 Authors' conclusions The publication date for this report is June 8, 2017, with a corrigendum issued on July 27, 2017. See Publication History for details. Cryoablation of the prostate gland provides a minimally invasive treatment option for the management of localized prostate cancer. The technique uses percutaneously

2018 Health Technology Assessment (HTA) Database.

186. Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer

Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer Purpose It is clinically challenging to integrate genomic-classifier results that report a numeric risk of recurrence into treatment recommendations for localized prostate cancer, which are founded in the framework of risk groups. We aimed to develop a novel clinical-genomic risk grouping system that can readily be incorporated into treatment guidelines for localized (...) prostate cancer. Materials and Methods Two multicenter cohorts (n = 991) were used for training and validation of the clinical-genomic risk groups, and two additional cohorts (n = 5,937) were used for reclassification analyses. Competing risks analysis was used to estimate the risk of distant metastasis. Time-dependent c-indices were constructed to compare clinicopathologic risk models with the clinical-genomic risk groups. Results With a median follow-up of 8 years for patients in the training cohort

2018 EvidenceUpdates

187. Risk of prostate cancer across different racial/ethnic groups in men with diabetes: a retrospective cohort study (Full text)

Risk of prostate cancer across different racial/ethnic groups in men with diabetes: a retrospective cohort study To examine the associations between prostate cancer, diabetes and race/ethnicity.Using administrative data from British Columbia, Canada for the period 1994 to 2012, we identified men aged ≥50 years with and without diabetes. Validated surname algorithms identified men as Chinese, Indian or of other race/ethnicity. Multivariable Cox regression was used to estimate adjusted risks (...) of prostate cancer according to diabetes status and race/ethnicity.Our cohort of 160 566 men had a mean (sd) age of 64.7 (9.4) years and a median of 9 years' follow-up. The incidence rates of prostate cancer among those with and without diabetes were 177.4 (171.7-183.4) and 216.0 (209.7-222.5) per 1000 person-years, respectively. The incidence among Chinese men was 120.9 (109.2-133.1), among Indian men it was 144.1 (122.8-169.0) and in men of other ethnicity it was 204.8 (200.2-209.5). Diabetes

2018 EvidenceUpdates PubMed

188. Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database (Full text)

Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database The aim of this study is to describe the trends and factors that influence the initial treatment of men with localized prostate cancer (PC) in the United States between 2004 and 2014.The National Cancer Institute's Surveillance, Epidemiology and End Results database was used to identify patients with primary prostate adenocarcinoma between 2004 and 2014. Patients were staged (...) in accordance with the American Joint Committee on Cancer 7th edition criteria and stratified according to the National Comprehensive Cancer Network guidelines risk group classification. Descriptive statistics describing treatment patterns by year of diagnosis, age, risk group, insurance status, and region were performed.A total of 460,311 male patients were identified with sufficient information to be categorized into National Comprehensive Cancer Network risk groups. Overall, 30.9% of patients had low

2018 Advances in radiation oncology PubMed

189. Current and Future Burden of Prostate Cancer in Songkhla, Thailand: Analysis of Incidence and Mortality Trends From 1990 to 2030 (Full text)

Current and Future Burden of Prostate Cancer in Songkhla, Thailand: Analysis of Incidence and Mortality Trends From 1990 to 2030 Prostate cancer is the second most common malignancy among men worldwide, and it poses a significant public health burden that has traditionally been limited mostly to developed countries. However, the burden of the disease is expected to increase, affecting developing countries, including Thailand. We undertook an analysis to investigate current and future trends (...) of prostate cancer in the province of Songkhla, Thailand, using data from the Songkhla Cancer Registry from 1990 to 2013.Joinpoint regression analysis was used to examine trends in age-adjusted incidence and mortality rates of prostate cancer and provide estimated annual percent change (EAPC) with 95% CIs. Age-period-cohort (APC) models were used to assess the effect of age, calendar year, and birth cohort on incidence and mortality rates. Three different methods (Joinpoint, Nordpred, and APC) were used

2018 Journal of global oncology PubMed

190. Targeting protein myristoylation for the treatment of prostate cancer (Full text)

Targeting protein myristoylation for the treatment of prostate cancer 29556510 2018 11 14 2331-4737 5 1-2 2018 Jan Oncoscience Oncoscience Targeting protein myristoylation for the treatment of prostate cancer. 3-5 10.18632/oncoscience.391 Sulejmani Essilvo E Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens,Athens, GA 30602, USA. Cai Houjian H Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia (...) , Athens,Athens, GA 30602, USA. eng R01 CA172495 CA NCI NIH HHS United States Editorial 2018 01 22 United States Oncoscience 101636666 2331-4737 B13 N-myristoyltransferase Src kinase myristoyl-CoA prostate cancer CONFLICTS OF INTEREST E. Sulejmani and H. Cai have no conflicts of interest to report. 2018 01 15 2018 01 15 2018 3 21 6 0 2018 3 21 6 0 2018 3 21 6 1 epublish 29556510 10.18632/oncoscience.391 391 PMC5854285 Nat Commun. 2014 Sep 26;5:4919 25255805 J Biol Chem. 2017 Nov 10;292(45):18422-18433

2018 Oncoscience PubMed

191. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. (Full text)

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. To develop and validate a genetic tool to predict age of onset of aggressive prostate cancer (PCa) and to guide decisions of who to screen and at what age.Analysis of genotype, PCa status, and age to select single nucleotide polymorphisms (SNPs) associated with diagnosis. These polymorphisms were incorporated into a survival analysis to estimate their effects on age (...) at diagnosis of aggressive PCa (that is, not eligible for surveillance according to National Comprehensive Cancer Network guidelines; any of Gleason score ≥7, stage T3-T4, PSA (prostate specific antigen) concentration ≥10 ng/L, nodal metastasis, distant metastasis). The resulting polygenic hazard score is an assessment of individual genetic risk. The final model was applied to an independent dataset containing genotype and PSA screening data. The hazard score was calculated for these men to test prediction

2018 BMJ PubMed

192. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, ph

Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, ph Docetaxel and cabazitaxel improve overall survival compared with mitoxantrone in patients with metastatic castration-resistant prostate cancer. Custirsen (OGX011) is a second generation highly specific antisense oligonucleotide that inhibits (...) the production of clusterin, an antiapoptotic protein that is upregulated in response to chemotherapy and that confers treatment resistance. We aimed to assess whether custirsen in combination with cabazitaxel and prednisone increases overall survival in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel.In this randomised, open-label, international, phase 3 trial, men with radiographically documented metastatic castration-resistant prostate cancer that had

2018 EvidenceUpdates

193. Screening for Prostate Cancer*

Screening for Prostate Cancer* Screening for Prostate Cancer | National Guideline Clearinghouse success fail JUL Aug 12 2018 2019 30 Sep 2016 - 13 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed of volunteers and interested parties, and has expanded (...) ? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Synthesis Screening for Prostate Cancer Guidelines Being Compared: American College of Physicians (ACP) Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. 2013 Apr

2018 National Guideline Clearinghouse (partial archive)

194. Prostate cancer

Prostate cancer Prostate cancer - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Prostate cancer Last reviewed: February 2019 Last updated: September 2018 Summary Second leading cause of cancer mortality in men in the US. Uncommon in men aged under 50 years. Prostate-specific antigen and digital rectal examination are key diagnostic tools used in screening. Management may be expectant or definitive. In the US, overall (...) 5-year survival rate is around 100% for local- and regional-stage prostate cancer, and around 30% for distant-stage prostate cancer (based on data from 2007 to 2013). Definition A malignant tumour of glandular origin, situated in the prostate. It is most commonly seen in older men; between 2011 and 2015 the median age at diagnosis in the US was 66 years. National Cancer Institute; Surveillance, Epidemiology, and End Results program (SEER). SEER stat fact sheets: prostate cancer. 2018 [internet

2018 BMJ Best Practice

195. Management of locally advanced and metastatic prostate cancer

Management of locally advanced and metastatic prostate cancer Management of locally advanced and metastatic prostate cancer - Cancer Guidelines Wiki Skip Links Personal tools Search Navigation Cancer Council guidelines Methodology Hosted cancer guidelines Adolescents and Young Adult (AYA) guidelines Prevention Policies Social links Page actions Cite this guideline Cancer Council Australia Advanced Prostate Cancer Guidelines Working Party. Management of locally advanced and metastatic prostate (...) cancer. Sydney: Cancer Council Australia. [Version URL: , cited 2019 May 26]. Available from: . Management of locally advanced and metastatic prostate cancer Contents Download Clinical questions: Androgen deprivation therapy (ADT) Radiotherapy Radiotherapy and androgen deprivation therapy (ADT) Surgery Surgery plus androgen deprivation therapy Pathologic T3/T4 disease post radical surgery (Patients with extra capsular extension, seminal vesicle involvement or positive surgical margins) Node-positive

2018 Cancer Council Australia

196. High-intensity focused ultrasound (HIFU) ablation for the treatment of prostate cancer

High-intensity focused ultrasound (HIFU) ablation for the treatment of prostate cancer Dec2015 © EUnetHTA, 2015. Reproduction is authorised provided EUnetHTA is explicitly acknowledged 1 EUnetHTA Joint Action 3 WP4 Version 1.4, 05 April 2018 Rapid assessment of other technologies using the HTA Core Model ® for Rapid Relative Effectiveness Assessment HIGH-INTENSITY FOCUSED ULTRASOUND FOR THE TREATMENT OF PROSTATE CANCER Project ID: OTCA09 High-intensity focused ultrasound for the treatment (...) of prostate cancer Version 1.4, 05 April 2018 EUnetHTA Joint Action 3 WP4 2 DOCUMENT HISTORY AND CONTRIBUTORS Version Date Description V1.0 08/02/18 First draft. V1.1 13/02/18 Input from co-author has been processed. V1.2 23/02/18 Input from dedicated reviewers has been processed. V1.3 20/03/18 Input from external experts (and manufacturers has been processed). V1.4 05/04/18 Input from medical editor has been processed. Disclaimer The assessment represents a consolidated view of the EUnetHTA assessment

2018 EUnetHTA

197. Erleada for Castrate Resistant Prostate Cancer - Details

Erleada for Castrate Resistant Prostate Cancer - Details Erleada for Castrate Resistant Prostate Cancer - Details | CADTH.ca Find the information you need Erleada for Castrate Resistant Prostate Cancer - Details Erleada for Castrate Resistant Prostate Cancer - Details Project Number pCODR 10133 Brand Name Erleada Generic Name Apalutamide Strength 60 mg Tumour Type Genitourinary Indication Castrate Resistant Prostate Cancer Funding Request non-metastatic castrate resistant prostate cancer (nm

2018 CADTH - Pan Canadian Oncology Drug Review

198. Post-treatment impact and needs of prostate cancer survivors in Malaysia; a qualitative study (Full text)

Post-treatment impact and needs of prostate cancer survivors in Malaysia; a qualitative study There are limited studies conducted on the needs of cancer survivors in developing countries like Malaysia. This qualitative study aimed at exploring the post-treatment impact and needs of prostate cancer survivors.A qualitative study design was used. One in-depth interview and four focus group discussions were conducted with 24 prostate cancer survivors (age range: 58-79 years) from government (...) and private hospitals in Malaysia in 2013. Trained researchers used a topic guide to guide the interviews, which were audio-recorded, transcribed verbatim, checked and managed with Nvivo 10 software. A thematic approach was used to analyse the data.Three main themes emerged from the analysis: (a) impact of prostate cancer on the survivors, (b) support needed for coping and (c) information needs. Prostate cancer has an important impact on the survivors' lifestyle after treatment. Some of them have to live

2017 Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia PubMed

199. Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer (Full text)

Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer The purpose of this study is to report the long-term outcomes and toxicity results of a prospective trial of moderately hypofractionated, image guided radiation therapy (RT) for localized prostate cancer.Patients were enrolled between December 2006 and February 2012. Patients in group 1 were stage T1-T2b, had a Gleason score (GS) of 2 to 6 or 7 (3 + 4) with only 1 lobe involved (...) , and had prostate-specific antigen levels ≤10 ng/mL. Group 2 patients were stage ≥T2c, had a GS ≥7 (4 + 3), a GS 7 (3 + 4) involving both lobes, or a PSA >10 ng/mL and ≤30 ng/mL. All patients underwent transrectal ultrasound guided fiducial (Visicoil) placement prior to computed tomography/magnetic resonance imaging simulation. Daily cone beam computed tomography with online correction was used. The prescribed dose was 64 Gy in 20 fractions. The primary endpoint was acute and late toxicity

2017 Advances in radiation oncology PubMed

200. Destroying the androgen receptor (AR)-potential strategy to treat advanced prostate cancer (Full text)

Destroying the androgen receptor (AR)-potential strategy to treat advanced prostate cancer 29344555 2018 11 13 2331-4737 4 11-12 2017 Nov Oncoscience Oncoscience Destroying the androgen receptor (AR)-potential strategy to treat advanced prostate cancer. 175-177 10.18632/oncoscience.389 Narayanan Ramesh R University of Tennessee Health Science Center, Memphis, TN, USA. Ponnusamy Suriyan S University of Tennessee Health Science Center, Memphis, TN, USA. Miller Duane D DD University of Tennessee (...) Health Science Center, Memphis, TN, USA. eng Editorial 2017 12 28 United States Oncoscience 101636666 2331-4737 androgen receptor castration-resistant prostate cancer (CRPC) selective androgen receptor degraders (SARDs) ubiquitin proteasome pathway CONFLICTS OF INTEREST Ramesh Narayanan is a consultant of GTx, Inc. 2017 11 16 2017 11 16 2018 1 19 6 0 2018 1 19 6 0 2018 1 19 6 1 epublish 29344555 10.18632/oncoscience.389 389 PMC5769981 Elife. 2013 Apr 09;2:e00499 23580326 Science. 2009 May 8;324(5928

2017 Oncoscience PubMed